BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22489661)

  • 1. Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.
    Li G; Zhao J; Peng X; Liang J; Deng X; Chen Y
    Cancer Biother Radiopharm; 2012 May; 27(4):227-33. PubMed ID: 22489661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis induced by the methanol extract of Salvia miltiorrhiza Bunge in non-small cell lung cancer through PTEN-mediated inhibition of PI3K/Akt pathway.
    Ye YT; Zhong W; Sun P; Wang D; Wang C; Hu LM; Qian JQ
    J Ethnopharmacol; 2017 Mar; 200():107-116. PubMed ID: 28088493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
    Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
    Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non‑coding RNA FER1L4 inhibits cell proliferation and promotes cell apoptosis via the PTEN/AKT/p53 signaling pathway in lung cancer.
    Ouyang L; Yang M; Wang X; Fan J; Liu X; Zhang Y; Shu Y
    Oncol Rep; 2021 Jan; 45(1):359-367. PubMed ID: 33416121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.
    Shen WM; Yin JN; Xu RJ; Xu DF; Zheng SY
    Kaohsiung J Med Sci; 2019 Jul; 35(7):401-407. PubMed ID: 31001918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VAOS, a novel vanadyl complexes of alginate saccharides, inducing apoptosis via activation of AKT-dependent ROS production in NSCLC.
    Zhou L; Yi Y; Yuan Q; Zhang J; Li Y; Wang P; Xu M; Xie S
    Free Radic Biol Med; 2018 Dec; 129():177-185. PubMed ID: 30223019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyoxometalate SbW9 regulates proliferation and apoptosis of NSCLC cells via PTEN-dependent AKT signaling pathway.
    Sun HB; Xu L; Wang ZX; Zheng Y; Zhao Y; Yin YY; Han XL; Xu ZN
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7959-7967. PubMed ID: 31599421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased tissue factor expression is associated with reduced survival in non-small cell lung cancer and with mutations of TP53 and PTEN.
    Regina S; Valentin JB; Lachot S; Lemarié E; Rollin J; Gruel Y
    Clin Chem; 2009 Oct; 55(10):1834-42. PubMed ID: 19661141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
    Dragoj M; Bankovic J; Sereti E; Stojanov SJ; Dimas K; Pesic M; Stankovic T
    Invest New Drugs; 2017 Dec; 35(6):718-732. PubMed ID: 28733702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells.
    Li J; Zhang Y; Zhao J; Kong F; Chen Y
    Mol Cell Biochem; 2011 Nov; 357(1-2):31-8. PubMed ID: 21594648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis.
    Zhang R; Banik NL; Ray SK
    Brain Res; 2008 Nov; 1239():216-25. PubMed ID: 18804099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulated Mucin 1 alleviates paclitaxel resistance in non‑small cell lung cancer cells.
    Xu H; Gao H; Li H; Li D; Yuan W; Zhang L; Cheng P; Su X; Li Z; Wang G; Zhang T
    Mol Med Rep; 2020 Oct; 22(4):2966-2972. PubMed ID: 32945387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.
    Perez-Soler R; Kemp B; Wu QP; Mao L; Gomez J; Zeleniuch-Jacquotte A; Yee H; Lee JS; Jagirdar J; Ling YH
    Clin Cancer Res; 2000 Dec; 6(12):4932-8. PubMed ID: 11156254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma.
    King TC; Akerley W; Fan AC; Moore T; Mangray S; Hsiu Chen M; Safran H
    Cancer; 2000 Aug; 89(4):769-73. PubMed ID: 10951339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non‑coding RNA MEG3 inhibits cell migration and invasion of non‑small cell lung cancer cells by regulating the miR‑21‑5p/PTEN axis.
    Lv D; Bi Q; Li Y; Deng J; Wu N; Hao S; Zhao M
    Mol Med Rep; 2021 Mar; 23(3):. PubMed ID: 33495842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Anticancer Activity of Combined Use of Caffeic Acid with Paclitaxel Enhances Apoptosis of Non-Small-Cell Lung Cancer H1299 Cells in Vivo and in Vitro.
    Min J; Shen H; Xi W; Wang Q; Yin L; Zhang Y; Yu Y; Yang Q; Wang ZN
    Cell Physiol Biochem; 2018; 48(4):1433-1442. PubMed ID: 30064123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
    Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.